CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC-Chapel Hill to enable them to produce CD30 antibody. The modified T cells, called ATLCAR.CD30, will be able to target and attach to lymphoma cancer cells that carry the CD30 antigen. Once they are attached, the hope is that the T cells will attack and destroy the lymphoma cancer cells. To prepare the body for the ATLCAR.CD30 cells, participants will complete lymphodepletion with two chemotherapy agents. Lymphodepletion will happen over three days prior to ATLCAR.CD30 infusion. If participants respond to this treatment, and there are sufficient unused ATLCAR.CD 30 cells, they may be eligible to receive a second infusion. The second infusion will be given after a second lymphodepletion chemotherapy. Most of the clinic visits in this research will last between 1-8 hours. There are risks associated in participating in this research study. Risks of treatment include infection, fever, nausea, vomiting, neurotoxicity, and cytokine release syndrome which can include low blood pressure or difficulty breathing. Other risks are associated with study procedures, such as biopsies, imaging, infusion, and breach of confidentiality.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraża pisemną zgodę na udział w badaniu.
- •Pacjent ma ukończone 18 lat.
- •Pacjent przeszedł co najmniej dwie wcześniejsze terapie z powodu chłoniaka.
- •U pacjenta potwierdzono obecność chłoniaka obwodowych komórek T, który reaguje na terapię anty-CD30.
- •Pacjent ma dobry ogólny stan zdrowia (Karnofsky >60%).
✗ Disqualifies
- •Pacjenci, którzy nie ukończyli 18 lat.
- •Pacjenci z innymi chorobami, które mogą wpływać na ocenę bezpieczeństwa terapii.
- •Kobiety w ciąży lub karmiące piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- September 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, United States
Wake Forest Baptist Medical Center
Winston-Salem, United States
Trial contact
Lori Stravers
Shamina Williams
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.